Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
- UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source.
SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.
UroSuite includes Myriad’s , and . The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients.
“Today’s launch of UroSuite reinforces Myriad Genetics’ commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists,” said Paul J. Diaz, president and CEO, Myriad Genetics. “We continue to build on our efforts to elevate our products to their full potential and introduce new innovative solutions and analytics to help patients and healthcare providers with personalized genetic insights and data-driven medical information.”
“There are educational and utilization gaps in the adoption of genetic testing in prostate cancer. Clinicians now have access to tools that can assist them with turnaround times and report interpretation, thereby aligning with national guidelines on genetic testing,” added Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic Research Center and Chief Medical Officer, Surgical Oncology/Urology, GenesisCare, U.S. “The UroSuite portfolio provides genetic insights based on gene expression biomarkers, comprehensive germline testing, and tumor profiling, facilitating more streamlined reporting, and thus enhancing the potential for personalized patient treatment.”
With UroSuite, providers can:
- Order multiple Myriad tests and receive a timely one-sheet summary of results through an online portal.
- Use the , Myriad’s health data intelligence platform that combines germline, somatic and HRD genetic data to help accelerate the pace of precision cancer research and equitable advancements in patient care. More than 100K+ Prolaris results are expected to be added to the registry in Q1 2023.
- Connect with genetic counselors and clinical experts who can provide educational support and answer questions.
For more information about UroSuite and Myriad Genetics’ other prostate cancer care offerings, visit: /UroSuite-LUGPA.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit .
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, UroSuite, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of UroSuite™ to patients and healthcare providers and the expectation that more than 100K+ Prolaris results will be added to the Precise Treatment Registry in Q1 2023. These “forward-looking statements” are based on management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Megan Manzari
(385) 318-3718
Investor Contact:
Matt Scalo
(801) 584-532
